Enterprise Risk management

1)Discussion Question : 250 words , APA 7 format. The key proposed NPRM revision of the Common Rule’s definition of “human subject” was to include all biospecimens, regardless of identifiability. Why is this crucial? Can you give examples? Textbook : Information Governance: Concepts, Strategies and Best Practices; John R.S. Fraser, Betty J. Simkins, Kristina Narvaez; Copyright © 2015 by John R.S. Fraser, Betty J. Simkins, Kristina Narvaez (ISBN 978-1-118-69196-0) Write response to below two Discussions: 2)Discussion response 1 : 125 words Medical biocontainment is predicated upon having human subject tests were done on any human subject‖which currently require biopsies to be obtained. Biopsies, by the way, also can be used to determine identity‖and determine if human subjects are involved in an experiment. This particular part of the NPRM proposal says that biopsies are not required, and samples of subject biological materials do not require lab ethics review. It also states that bioburden is not a requirement for continuing the study of an individual unless it is unavoidable. The larger context of this proposed rule is the current debate around human subject research, its connection to large scale, trans-national research agencies like the NIH, and to use of human subjects in DOE research and energy policy, as these agencies are defined in the current NPRM's definitions (Suk, Schiler, & Kensek, 2017). A provision in the proposed rule that is troubling in its broad language, and seemingly designed to make it easier for the research subjects to be sexually harassed, is its reference to the emotional distress a participant caused For example, the current Human Subject Research Protection Act (HSRPA) was enacted to ensure that human subjects are safe when they are involved in research involving research that has a significant scientific, medical, or industrial impact on them, and to protect human subjects from being subject to unwarranted interference from others in the research process. While there is some question as to whether the ability to infringe upon a human subject's right of privacy requires that the person be told that the study is on him/her‖the current legislation is broadly phrased to meet this requirement. The proposed rule goes beyond these protections' boundaries by presuming that the review for non-consensual research involving a human subject is mandatory and that non-consensual research involving a human subject is always unconsented to. The proposed rule includes a broad and vaguely-defined, set of factors that are considered when determining whether or not research involving a human subject is consensual (Choudhury et al., 2018). References Suk, J. Y., Schiler, M., & Kensek, K. (2017). Investigation of existing discomfort glare indices using human subject study data. Building and Environment, 113, 121-130. Choudhury, O., Sarker, H., Rudolph, N., Foreman, M., Fay, N., Dhuliawala, M., ... & Das, A. K. (2018). Enforcing human subject regulations using blockchain and smart contracts. Blockchain in Healthcare Today, 1, 1-14. 3)Discussion response 2 : 125 words The concept of data subject privilege is, therefore, not limited to diagnostic or other biological specimens. In this situation, a biospecimen that is essentially, but not necessarily, diagnostic in origin but is personally identifiable is still relevant for data protection purposes. Also, such specimens that are of experimental or other interest to the investigator may not meet the idea of identifiable. When the Human Subject Protection Act (HSPCA) included all biospecimens in terms of their medical utility, particularly in clinical research, the industry was immediately outraged, claiming it would affect the profitable 'best practice' practice of exclusively studying human subjects. However, since the HSPCA has nothing to do with the development of drugs, the amendment instead alters how money-making' biospecimens are sold to the research community. Because except for indeterminate data, a biospecimen from any source that can be used to diagnose or diagnose disease is an identifiable human subject (Petersen, 2017). A bone or tissue culture also has the additional attribute of being for the development of life. It is a human cell culture not because it is human tissue but because it is for the development of life. This concept is important because the inclusion of bioreactors or bioreactor manufacturing facilities is unnecessary. Where more than one biospecimen has been developed from the same subject, the biospecimen with the greater potential for function or quality control has been legally designated as the subject for registration under the Proposed NPRM and, therefore, is protected under the Proposed NPRM. This new policy statement on human subject protection applies to all life-stage research that might involve an intact human subject. The proposal in the NPRM made a few changes to the definition of a human subject. It was modified to read: A human subject means any individual subject to an investigation under this part, whether or not the individual was specifically named in the written authorization for the investigation. Subject subjects include individuals involved in research and medical care, volunteers, participants in research or clinical studies, any individual of unrestricted interest who has been or may be involved in the research (Huang et al., 2017). References Huang, T., Li, J., Xie, Y., Niu, J., & Mak, C. M. (2017). Simultaneous environmental parameter monitoring and human subject survey regarding outdoor thermal comfort and its modeling. Building and Environment, 125, 502-514. Petersen, S. (2017). Human subject review standards and procedures in international research: Critical ethical and cultural issues and recommendations. International Perspectives in Psychology: Research, Practice, Consultation, 6(3), 165.